Stock Market 21 May 2026

Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next
····

Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next

Arcturus Therapeutics traded at $7.81 in pre-market Tuesday, up 0.5% from Monday’s close after a 1.9% drop the previous session. The company will present at the Jefferies healthcare conference June 4 and hold its annual meeting June 5. Quarterly revenue fell to $2.1 million from $29.4 million a year earlier, with cash at $213.4 million as of March 31. Investors remain focused on trial progress and cash runway.
June 2, 2026
Kolibri Global Energy Shares Dip Despite Oil Move
····

Kolibri Global Energy Shares Dip Despite Oil Move

Kolibri Global Energy shares fell 10 cents to $6.14 in midday Nasdaq trading Thursday, despite reporting record first-quarter net revenue of $19.6 million. Net income dropped to $4 million after a $2.9 million unrealized loss on commodity contracts. Oil prices climbed about 3% on renewed Iran supply concerns. Kolibri’s production averaged 4,685 BOEPD, with three new wells being drilled.
May 21, 2026
Corsair Shares Drop Despite Margin Recovery
····

Corsair Shares Drop Despite Margin Recovery

Corsair Gaming shares fell 1.5% to $6.78 Thursday morning in New York, lagging tech peers ahead of a June 4 investor meeting. March-quarter revenue dropped 4.1% to $354.5 million, but gross margin rose to 32.7%. Net income reached $13.1 million, reversing a loss last year. The company repurchased 0.9 million shares for $5 million in Q1.
May 21, 2026
LSH Shares Fall After Profit Turnaround – Nasdaq Risk in Focus
····

LSH Shares Fall After Profit Turnaround – Nasdaq Risk in Focus

Lakeside Holding shares dropped 10.6% to $0.514 Thursday, valuing the company at $17.7 million and keeping it below Nasdaq’s $1 minimum with a July 7 compliance deadline. Quarterly revenue jumped 167% to $1.33 million, with net income of $142,408, but continuing operations posted a $1.58 million loss. The company has shifted focus to pharmaceutical distribution in China.
May 21, 2026
UBCP Stock Slips Despite Dividend Yield: What United Bancorp Investors Are Watching Now
····

UBCP Stock Slips Despite Dividend Yield: What United Bancorp Investors Are Watching Now

United Bancorp Inc. shares dropped 1.25% to $14.24 in late-morning trading Thursday on volume of 146 shares. The move comes ahead of a June 19 dividend payout of $0.195 per share, up 5.4% from last year. First-quarter net income rose 2.1% to $1.911 million, but nonaccrual and overdue loans climbed to $6.8 million. Noninterest expense increased 10.2%, partly due to office and digital investments.
May 21, 2026
Canaan Stock Drops After Q1 Loss Widens — Why CAN Is Under Pressure Now
····

Canaan Stock Drops After Q1 Loss Widens — Why CAN Is Under Pressure Now

Canaan shares fell 5.3% to $0.4127 in late-morning Nasdaq trading Thursday after the company reported a first-quarter net loss of $88.7 million and forecast weaker Q2 revenue of $35 million to $45 million. First-quarter revenue dropped to $62.7 million from $196.3 million in the prior quarter. Trading volume reached 3.8 million shares. Several bitcoin-mining peers rose.
May 21, 2026
Quantum Shares Tick Up in Pre-Market Trade After AI Storage Angle Draws Notice
····

Quantum Shares Tick Up in Pre-Market Trade After AI Storage Angle Draws Notice

Quantum Corp shares climbed 5.88% to $8.64 in pre-market trading Thursday after closing 5.84% higher Wednesday. No new company news accompanied the move. Quantum last reported fiscal Q3 revenue of $74.6 million and a GAAP net loss of $27.8 million. The company’s market value stands near $112 million, far below larger peers NetApp and Dell.
May 21, 2026
Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
····

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders

Bright Minds Biosciences shares jumped 11.1% to $82.78 after Piper Sandler raised its price target to $220 and reiterated an “Overweight” rating. The company reported C$309.7 million in cash at March 31, up from C$82.9 million in September, and a wider net loss. Lead drug BMB-101 completed Phase 1 and reported Phase 2 data for epilepsy and absence seizures.
May 21, 2026
Spark I gets Nasdaq notice ahead of Kneron deadline
····

Spark I gets Nasdaq notice ahead of Kneron deadline

Spark I Acquisition Corp disclosed it fell below Nasdaq’s minimum 400-holder requirement, triggering a compliance notice received May 14. Shares closed Wednesday at $12.40, about 8.9% above redemption value, with a $107.37 million market cap. The company has 45 days to submit a compliance plan and is negotiating a merger with Kneron Holding Corporation. Spark reported no revenue and a $94,195 net loss for Q1.
May 21, 2026
Bio-Techne Shares Bounce, Investors Eye a Key Risk
····

Bio-Techne Shares Bounce, Investors Eye a Key Risk

Bio-Techne closed Wednesday at $46.70, up 2.7%, marking a three-day rebound but still 35% below its January high. Fiscal third-quarter revenue fell 2% to $311.4 million, missing Wall Street estimates as weak biotech demand and U.S. academic funding cuts weighed on sales. CEO Kim Kelderman described the academic market as “frail” and not on a clear recovery path. Bio-Techne owns 20% of Wilson Wolf and may acquire the rest.
May 21, 2026
Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead
····

Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead

Aterian shares fell 2.5% to $1.15 in premarket trading Thursday after a May 15 filing showed a wider first-quarter loss and raised “substantial doubt” about its ability to continue. The company is seeking stockholder approval to sell major brands for $18 million and issue $7 million in preferred stock, moves that could give investor David E. Lazar control of over 95% of the company.
May 21, 2026
Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
····

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data

Vanda Pharmaceuticals shares fell 0.5% to $6.15 in premarket trading Thursday, trimming part of Wednesday’s 3.2% gain. First-quarter net product sales rose 3% to $51.7 million, but the company posted a $48.6 million net loss and used $50.2 million in operating cash. Vanda raised 2026 revenue guidance to $240–$290 million, expecting Nereus to contribute up to $30 million this year.
May 21, 2026
EHGO Shares Approach 52-Week Lows as Eshallgo Pops Up on Nasdaq Radar Again
····

EHGO Shares Approach 52-Week Lows as Eshallgo Pops Up on Nasdaq Radar Again

EHGO closed at $1.55 on Wednesday, down 4.32%, after hitting a 52-week low of $1.42. The Nasdaq-listed company recently regained compliance with minimum bid rules after a 16-for-1 reverse split. Shareholders approved raising Class B voting rights to 400 votes per share and authorized further share consolidations. Eshallgo’s market value stands near $3.14 million.
May 21, 2026
LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News
····

LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News

Liminatus Pharma agreed to acquire InnocsAI in an all-stock deal, issuing 1.6 billion shares at $0.20 each—over 35 times its current share count. LIMN rose 51% to $0.2844 in premarket trading. The deal would add CAR-T cancer therapy assets, including a candidate authorized for a Phase 1/2a study in South Korea. Liminatus reported $1.91 million in cash and warned of “substantial doubt” about its ability to continue.
May 21, 2026
Cintas Stock Just Lost Its Rebound — Why CTAS Traders Are Watching the UniFirst Deal
····

Cintas Stock Just Lost Its Rebound — Why CTAS Traders Are Watching the UniFirst Deal

Cintas shares closed Wednesday at $171.36, down 0.49%, after giving back gains from a 3.68% jump Monday. The stock lagged the S&P 500, which rose 1.1% the same day. Investors are watching Cintas’ pending $5.5 billion UniFirst acquisition and projected $375 million in cost synergies. Cintas reported fiscal Q3 revenue of $2.84 billion, up 8.9%, and raised its full-year outlook.
May 21, 2026
1 … 16 17 18 19 20 … 126

Stock Market Today

  • British American Tobacco Shares Drop 4% Amid Lowered Volume Forecasts
    June 2, 2026, 8:38 AM EDT. British American Tobacco's (LSE:BATS) shares fell 4% following a trading update that cut 2026 cigarette volume projections from a 2% to 2.5% decline. The FTSE 100 tobacco giant, which had gained 32% over the past year, attributes the sharper volume drop to rising health concerns and tightening regulations on combustible products worldwide, particularly in emerging Asian markets. Despite the setback, the company remains optimistic about revenue growth prospects from non-combustible products, such as Vuse vapes and Velo gum, which exceeded first-half sales expectations. BAT now anticipates full-year results at the lower end of its medium-term guidance: 3%-5% revenue growth and 4%-6% adjusted operating profit growth.